Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Prognostic Significance and Risk Stratification in Acute Myeloid Leukaemia Patients in the Absence of Successful Cytogenetic Analysis

Lucy Chilton, PhD, Christine Harrison, PhDFRCPath FMedSci, Anthony V. Moorman, PhD, Iona Ashworth, Alan K. Burnett, MD FRCP, David Grimwade, PhD FRCPath, Robert K Hills, MA MSc DPhil

Blood (2015) 126 (23): 1379.

https://doi.org/10.1182/blood.V126.23.1379.1379

Published: 2015

Journal Articles

Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials

Khan Naeem, PhD, Robert K. Hills, MA, MSc, DPhil, Paul Virgo, BSc,, Stephen Couzens, Nithiya Clark, Amanda Gilkes, Angela Grech, Peter Richardson, Steven Knapper, David Grimwade, PhD FRCPath, Nigel H. Russell, MD, Alan K. Burnett, MDFRCP, Sylvie Freeman, PhDFRCPath

Blood (2015) 126 (23): 320.

https://doi.org/10.1182/blood.V126.23.320.320

Published: 2015

Journal Articles

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Alan K Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jamie Cavenagh, Jonathan Kell, MD MB, Gail Jones, Asim Khwaja, FRCPath, Mary Frances McMullin, MDFRCPath,FRCP, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 2308.

https://doi.org/10.1182/blood.V124.21.2308.2308

Published: 2014

Journal Articles

Integrated Nuclear Proteomics and Transcriptomics Identifies New High Frequency Dysregulated Transcription Factors in AML

Chinmay R Munje, BSc PhD, Andrew J. K. Williamson, BSc, PhD, Samuel Taylor, BSc, PhD, Robert K. Hills, MA, MSc, DPhil, Steven Knapper, DM BMBCh, Alan K. Burnett, MD, Andrew Pierce, BSc, PhD, Anthony Whetton, BSc, PhD, Richard L. Darley, BSc PhD, Alex Tonks, BSc PhD

Blood (2014) 124 (21): 3554.

https://doi.org/10.1182/blood.V124.21.3554.3554

Published: 2014

Journal Articles

The Impact of Different DNMT3A Mutations on Outcome in Younger Adults with Acute Myeloid Leukemia

Rosemary E Gale, Katarina Lamb, BSc, Christopher Allen, BSc, Dima El-Sharkawi, MBBS, Cassandra Stowe, MSc, Sarah Jenkinson, MSc, Steven Tinsley, PhD, Glenda Dickson, PhD, Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, David C Linch, FMedSci

Blood (2014) 124 (21): 67.

https://doi.org/10.1182/blood.V124.21.67.67

Published: 2014

Journal Articles

A Subpopulation of Blasts with Attenuated p38 MAPK Response Is Seen in Virtually All AML Patients and AML Cell Lines and Is Defined By Cells with Augmented Lipid-Associated Anti-Oxidant Defense

Paul S. Hole, PhD, Sara Davies, MSc, Chinmay R Munje, BSc PhD, Sandra Kreuser, BSc, Robert K. Hills, MA MSc DPhil, Nader Omidvar, PhD, Steven Knapper, DM BMBCh, Alan K. Burnett, MDFRCP, Alex Tonks, BSc PhD, Richard L. Darley, BSc PhD

Blood (2014) 124 (21): 785.

https://doi.org/10.1182/blood.V124.21.785.785

Published: 2014

Journal Articles

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Alan K. Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jonathan Kell, MD MB, Jamie Cavenagh, Lars Kjeldsen, MD PhD, Mary Frances McMullin, MDFRCPath, FRCP, Paul Cahalin, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 7.

https://doi.org/10.1182/blood.V124.21.7.7

Published: 2014

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

Michael Dennis, MD, Nigel H. Russell, MD, Nicki Panoskaltsis, MD, Claire Jane Hemmaway, MD, Donald Milligan, MD, Richard E Clark, MBBS MD, Robert K. Hills, MA MSc DPhil, Alan K Burnett, MD

Blood (2014) 124 (21): 3747.

https://doi.org/10.1182/blood.V124.21.3747.3747

Published: 2014

Journal Articles

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

Alan K. Burnett, MD, David Bowen, MD, PhD, Nigel Russell, MD, Steven Knapper, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Asim Khwaja, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Dominic Culligan, Helen Clark, Robert K. Hills, MA, MSc, DPhil

Blood (2013) 122 (21): 622.

https://doi.org/10.1182/blood.V122.21.622.622

Published: 2013

Journal Articles

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

Robert K. Hills, MA, MSc, DPhil, Stephen Petersdorf, MD, Elihu H. Estey, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Sylvie Castaigne, Herve Dombret, MD, PhD, Sylvie Chevret, Jacques Delaunay, MD, Norbert Ifrah, Jean-Yves Cahn, MD, PhD, Christian Recher, MD, Alan K Burnett, MD

Blood (2013) 122 (21): 356.

https://doi.org/10.1182/blood.V122.21.356.356

Published: 2013

Journal Articles

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Nigel Russell, MD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Richard E. Clark, MBBS, MD, FRCP, FRCPath, David Bowen, MD, PhD, Mary Frances McMullin, MD

Blood (2013) 122 (21): 358.

https://doi.org/10.1182/blood.V122.21.358.358

Published: 2013

Journal Articles

Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

Roland B Walter, MD, PhD, Megan Othus, PhD, Alan K. Burnett, MD, Bob Löwenberg, MD, PhD, Hagop M. Kantarjian, MD, Gert J. Ossenkoppele, MD PhD, Robert K. Hills, MA, MSc, DPhil, Farhad Ravandi, MD, Anna Evans, PhD, Sherry R. Pierce, RN, BS, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2013) 122 (21): 64.

https://doi.org/10.1182/blood.V122.21.64.64

Published: 2013

Journal Articles

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Lone S. Friis, MD, PhD, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Michelle Lazenby, Amanda F Gilkes, MSc, David Bowen, MD, PhD, Nigel Russell, MD

Blood (2013) 122 (21): 493.

https://doi.org/10.1182/blood.V122.21.493.493

Published: 2013

Journal Articles

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Blood (2013) 122 (21): 52.

https://doi.org/10.1182/blood.V122.21.52.52

Published: 2013

Journal Articles

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Alan K Burnett, MD, ChB, FRCP, FRCPath, FMedSci, Nigel H. Russell, MD, Mary Frances McMullin, MD, Jonathan Kell, MD, MB, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Paul Moreton, Andrew H Wei, MBBS, PhD, Lars Kjeldsen, MD, PhD, Robert K. Hills, MA, MSc, DPhil

Blood (2012) 120 (21): 889.

https://doi.org/10.1182/blood.V120.21.889.889

Published: 2012

Journal Articles

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Alan K. Burnett, MD, Nigel H Russell, MD, Jonathan Kell, MD, MB, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Paul Cahalin, Robert K. Hills, MA, MSc, DPhil

Blood (2012) 120 (21): 892.

https://doi.org/10.1182/blood.V120.21.892.892

Published: 2012

Journal Articles

Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center

Roland B. Walter, MD, PhD, Megan Othus, PhD, Alan K. Burnett, MD, Bob Löwenberg, MD, PhD, Hagop M. Kantarjian, MD, Gert J. Ossenkoppele, MD, PhD, Robert K. Hills, MA, MSc, DPhil, Kees G.M. van Montfort, PhD, Farhad Ravandi, MD, Anna Evans, PhD, Sherry A. Pierce, RN, BS, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2012) 120 (21): 540.

https://doi.org/10.1182/blood.V120.21.540.540

Published: 2012

Journal Articles

Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials

Nigel H Russell, MD, Robert K. Hills, MA, MSc, DPhil, Lars Kjeldsen, MD, PhD, John L Yin, MD, Charles Craddock, Alan K Burnett, MD

Blood (2012) 120 (21): 231.

https://doi.org/10.1182/blood.V120.21.231.231

Published: 2012

Journal Articles

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia

Charles F. Craddock, MD PhD, Nicolas Goardon, PhD, Lynn Quek, MD, Sylvie Freeman, MD, PhD, Shamyla Siddique, Manoj Raghavan, Anna Schuh, PhD, David Grimwade, PhD, Robert K Hills, MA, MSc, DPhil, Cassandra Brookes, PhD, Michael Griffiths, PhD, James D. Cavenagh, MD, Ravindra Majeti, MD, PhD, Irving L. Weissman, MD, Alan K Burnett, MD, Paresh Vyas

Blood (2011) 118 (21): 638.

https://doi.org/10.1182/blood.V118.21.638.638

Published: 2011

NARROW

Prognostic Significance and Risk Stratification in Acute Myeloid Leukaemia Patients in the Absence of Successful Cytogenetic Analysis

Significance of Blast CD33 Expression for Effect of Gemtuzumab Ozogamicin at Different Doses in Adult Acute Myeloid Leukemia: Results from the UK NCRI AML16/17 Trials

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m 2 and 6mg/m 2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial

Integrated Nuclear Proteomics and Transcriptomics Identifies New High Frequency Dysregulated Transcription Factors in AML

The Impact of Different DNMT3A Mutations on Outcome in Younger Adults with Acute Myeloid Leukemia

A Subpopulation of Blasts with Attenuated p38 MAPK Response Is Seen in Virtually All AML Patients and AML Cell Lines and Is Defined By Cells with Augmented Lipid-Associated Anti-Oxidant Defense

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia

AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

Reasons For Survival Improvement In Core Binding Factor AML: A 25 Year Analysis Of The UK MRC/NCRI AML Trials

Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center

Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only